Neuropathic and Inflammatory Pain Therapeutics Targeting Adenylyl Cyclase

Back to all technologies
Download as PDF
2015-DAI-67035
Chronic pain, such as neuropathic pain, is common in multiple diseases and is a major health concern. Due the multifaceted nature of pain, its basic mechanism is poorly understood; therefore, current therapies are do not meet the needs of many patients. Researchers have identified adenylyl cyclase type 1 (AC1) as a potential target for pain therapy. This enzyme is present in neurons, but not in heart, liver, or kidney cells, which would minimize side effects of AC1 inhibitors to non-neuronal tissues. Currently, only one inhibitor against AC1, called NB001, has been identified. There is a need to identify new therapeutics that target AC1.

Researchers at Purdue University have developed a series of compounds that inhibit AC1 in cell culture with IC50 values in the low micromolar range. In addition, these new AC1 inhibitors can be produced via mild and efficient reaction chemistry with high regioselectivity, stereoselectivity, and excellent yield. This new technology will not only facilitate chronic pain therapy but provides an effective synthetic route to optimize these lead compounds.

Advantages:
-Potential first in class therapeutic for neuropathic and inflammatory pain
-Fewer predicted side effects

Potential Applications:
-Chronic pain therapy
-Pharmaceutical industry

Related Publication:
Zhishi Ye et al., Palladium-Catalyzed Regio- and Stereoselective γ-Arylation of Tertiary Allylic Amines: Identification of Potent Adenylyl Cyclase Inhibitors
Org. Lett., 2015, 17 (4), pp 892–895
Mar 14, 2018
CON-Patent
United States
10,144,700
Dec 4, 2018

Feb 16, 2016
Utility Patent
United States
10,100,001
Oct 16, 2018

Feb 16, 2015
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org